DeepScribe vs Regeneron Pharmaceuticals
Side-by-side comparison of AI visibility scores, market position, and capabilities
San Francisco ambient AI scribe using smartphone to listen to patient visits; generates structured EHR notes within minutes, customizable to each physician's documentation style.
About
DeepScribe is a San Francisco-based ambient AI medical scribe company that uses machine learning to listen to physician-patient conversations and automatically generate complete, structured clinical documentation without physician dictation or manual entry. The platform runs on a smartphone placed in the exam room, processes the conversation to identify medically relevant information, and presents a complete draft note in the EHR within minutes of the visit ending. DeepScribe differentiates through its customization capabilities — physicians can train the AI to match their personal documentation style, preferred note templates, and specialty-specific terminology, making the output immediately publishable with minimal editing. The company serves primary care, specialty, and urgent care physicians as well as telehealth providers. Founded in 2017, DeepScribe raised over $30M from investors including Kaiser Permanente Ventures, Greycroft, and SignalFire. The company has demonstrated significant time savings for clinicians and reductions in EHR-related stress. It competes with Suki AI, Nuance DAX, and Freed AI in the ambient medical scribe market.
Regeneron (REGN) reported $13.9B revenue in FY2024, up 7% YoY. Top biotech company. Dupixent franchise >$14B. Leaders in eye disease, immunology, oncology. HQ: Tarrytown, NY.
About
Regeneron Pharmaceuticals, Inc. is a leading biotechnology company specializing in the discovery, development, and commercialization of medicines for serious diseases, headquartered in Tarrytown, New York. Founded in 1988 by Leonard Schleifer and George Yancopoulos, Regeneron developed its own proprietary drug discovery technology platform (VelociGene, VelocImmune) that has enabled the development of multiple breakthrough medicines. The company reported revenues of $13.9B in FY2024, up 7% year-over-year.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.